Access Pharmaceuticals, Milestone Biosciences, SpePharm sales and marketing update

Access said it ended a 2008 deal that gave Milestone exclusive rights to market MuGard in North America because Milestone failed to meet undisclosed milestones. Access is evaluating options for commercializing the product and has hired former Milestone President and CEO Frank Jacobucci to consult on the launch. It hopes to launch the product in North America by year end (see BioCentury, Aug. 25, 2008). ...